Active Biotech AB Interim Report January - June 2013

(Thomson Reuters ONE) -


Events during January - June 2013:

Laquinimod
· positive results from Phase IIa study of laquinimod in active lupus nephritis
· Teva plans continued clinical development of laquinimod for the treatment of
lupus nephritis
· data presented at AAN showed a slower disability progression for multiple
sclerosis patients who commenced early treatment with laquinimod compared with
delayed treatment

Tasquinimod
· analysis plan for Phase III trial updated; primary PFS analysis expected at
the same time as first interim overall survival analysis in 2014
· Phase II follow-up study shows an impact of tasquinimod on bone metastases as
measured by
Bone Scan Index (BSI); results presented at ASCO

ANYARA
· improved overall survival in a subgroup of renal cell cancer patients in the
Phase II/III study; results presented at ASCO

57-57 (paquinimod)
· clinical trial in systemic sclerosis concluded, evaluation under way

ISI
· patent applications filed

                 Jan - Jun Jan - Dec

 (MSEK)       2013       2012    2012
-------------------------------------------------------------------------------
*      Net sales             5.0          96.6   227.9

*      Operating loss       -156.5       -120.6  -163.2

*      Net loss       -159.2       -123.5  -175.0

*      Earnings per share (SEK)         -2.18         -1.79    -2.54

*      Cash and cash equivalents
(MSEK)
        389.1         383.7    216.7

  For further information, please contact:

  Tomas Leanderson, President and CEO
  Tel: +46 (0)46-19 20 95

  Hans Kolam, CFO
  Tel: +46 (0)46-19 20 44

  Active Biotech AB (Corp. Reg. No. 556223-9227)
  Box 724, SE- 220 07 Lund
  Tel: +46 (0)46-19 20 00
  Fax: +46 (0)46-19 11 00

  This report is also available at www.activebiotech.com


Active Biotech AB Interim Report January - June 2013:
http://hugin.info/1002/R/1721488/573320.pdf



This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE
[HUG#1721488]

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 07.08.2013 - 08:30 Uhr
Sprache: Deutsch
News-ID 285372
Anzahl Zeichen: 2996

contact information:
Town:

LUND

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 128 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Active Biotech AB Interim Report January - June 2013"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech